Skip to main content
. 2019 Apr 8;18:122. doi: 10.1186/s12936-019-2755-5

Fig. 4.

Fig. 4

Cost-effective prioritization of LLINs, treatment and the RTS,S vaccine. The average cost-effective scale-up of access to LLINs (blue bars), coverage of treatment (red bars) and the RTS,S vaccine (orange bars) for a medium (baseline PfPr2-10: 30%) and b high (baseline PfPr2-10: 60%) perennial transmission settings